Press Release

Study Demonstrates Feasibility of Cardiac Small Vein Mapping Using Baylis Medical 2-French Microcatheter

June 22, 2020

TORONTO, JUNE 22, 2020 – A recent study has demonstrated the feasibility of cardiac small vein mapping using Baylis Medical’s EPstar 2F Fixed Electrophysiology Catheter. The EPstar 2F microcatheter is the smallest commercially available diagnostic catheter in North America.

The study, titled Miniaturized Octopolar Catheter for Mapping in Cardiac Veins: Early Experience Guiding Ethanol Infusion in the Vein of Marshall and LV Summit Veins, was presented as a poster in the 2020 Heart Rhythm Sessions (HRS) online catalogue.

The research was led by Dr. Miguel Valderrabano, Chief of Cardiac Electrophysiology at Houston Methodist Hospital in Texas. Researchers used the 2F microcatheter for mapping and pacing from the Vein of Marshall (VOM), Left-Ventricular Summit (LVS) and epicardial veins. Researchers also found that the 2F catheter can characterize epicardial signals and verify ethanol induced ablation.

“Deep cardiac vein mapping is a key component in our ability to treat certain complex conditions,” said Dr. Valderrabano. “The EPstar catheters are the only multipolar catheters available small enough to undertake such small vein mapping.”

The EPstar catheter family includes a 2F microcatheter and a 6F guiding catheter which can be combined to allow deeper coronary sinus (CS) mapping. Deeper electrophysiological examination, including mapping, is often required to aid in the diagnosis of idiopathic ventricular tachycardias, complex atrial tachycardias, and left Wolff-Parkinson-White Syndrome. The 2F microcatheter also allows mapping and pacing in smaller anatomy such as the VOM.

“We are pleased to see our EPstar catheters making an impact on the lives of patients,” said Gareth Davies, Director of Advanced Development at Baylis. “Baylis’ commitment to filling the unmet needs of patients was a driving factor behind bringing the only 2F diagnostic catheter to the market. We are proud to have partnered with Japan Lifeline to bring this device to North America.”

About Baylis Medical
Baylis Medical is a leader in the development and commercialization of innovative cardiology devices that enable life-saving therapies. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.

About Japan Lifeline Co., Ltd.
Japan Lifeline (JLL) is a manufacturer and importer of medical devices specialized in the cardiovascular space with a track record of almost 40 years in Japan. The company’s proprietary products developed based on its wealth of experience on arrhythmias and cardiovascular surgeries have been highly evaluated and hold a top-class market share in Japan. Japan Lifeline is a publicly traded company, ticker symbol 7575 (TSE 1st Section). Visit the Japan Lifeline’s website at: http://www.japanlifeline.com.


PRM-00607 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2020. The Baylis Medical logo is a trademark and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Other trademarks are property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use